zanamivir, Relenza (cont.)
Omudhome Ogbru, PharmD
Omudhome Ogbru, PharmD
Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Medical and Pharmacy Editor:
DOSING: Zanamivir is administered by oral inhalation. The recommended dose is two inhalations (5 mg per inhalation) twice daily (approximately 12 hours apart) for five days. Two doses (separated by at least two hours) should be administered on the first day of treatment. For best results, treatment should begin as soon as symptoms develop. The recommended dose for prevention of influenza in a household setting is 10 mg once daily for 10 days. The recommended dose for preventing influenza in a community setting is 10 mg once daily for 28 days.
DRUG INTERACTIONS: Zanamivir potentially may interfere with the action of injections of live attenuated flu vaccine because zanamivir prevents viral replication. Therefore, live attenuated flu vaccine should not be administered from 2 weeks before to 48 hours after administration of zanamivir. Trivalent inactivated influenza vaccine can be administered while using zanamivir.
PREGNANCY: The Centers for Disease Control (CDC) states that pregnancy is not a contraindication for use of zanamivir in pregnant women because the benefits outweigh the risks.
NURSING MOTHERS: It is not known whether zanamivir is excreted in breast milk. However, the CDC recommends that nursing women who develop flu after child birth should be treated with antiviral drugs.
SIDE EFFECTS: The most frequent side effects are headaches, diarrhea, nausea, cough, vomiting, disturbance in temperature regulation, and dizziness. Sinusitis, ear, nose, and throat infections may occur. Skin reactions, muscle or joint pain, allergic reactions, bronchospasm, and behavioral disturbances have been reported. Patients with respiratory diseases may experience breathing problems when treated with zanamivir due to irritation of the breathing tubes by the particles from the inhaler. If breathing problems occur, zanamivir should be discontinued. Patients who have asthma or other breathing problems that make them sensitive to inhaled particles should have a fast acting, inhaled bronchodilator available to treat any breathing problem that may occur when zanamivir is used.
Medically Reviewed by a Doctor on 2/21/2014
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Back to Medications Index